A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects

This Phase I study is designed to evaluate the safety, tolerability, and pharmacokinetics of BAL2420 in healthy adult subjects. The primary objective is to characterize the safety profile and tolerability of the investigational product. Assessment of pharmacokinetics is essential to determine the absorption, distribution, metabolism, and excretion of the compound, which provides critical data for future clinical development in treating Gram-negative bacterial infections. 4, 6

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers, including both males and females, within the age range classified as adults. This population is identified as a vulnerable group. Individuals with severe infections caused by Gram-negative bacteria are excluded from the study.

This Phase I clinical trial is designed to evaluate the safety, tolerability, and pharmacokinetics of BAL2420 in healthy adult subjects. The study methodology involves a sequence of clinical assessments beginning with a screening visit to determine eligibility. Following recruitment, subjects will undergo scheduled study visits to monitor physiological responses and drug disposition. The trial includes follow-up assessments and concludes with an end-of-study visit. Total participant involvement is determined by the specific dosing regimen and required monitoring periods. Early termination of participation may occur if predefined safety criteria or protocol deviations are met.

Efficacy assessment in this clinical trial focuses on the management of severe infections caused by Gram-negative bacteria. The evaluation of therapeutic impact is conducted within the framework of a Phase 1 study design.